Skip to main content
    S

    Sophia Genetics SA (SOPH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $7.45
    +0.01 (+0.13%)

    Market Cap: $703.25M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Sophia Genetics SA (SOPH) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sophia Genetics SA (SOPH) has a market cap of $703.25M and an enterprise value of $660.44M. Its share count is up 26.14% from a year earlier. It kept -89.18% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 6.09% below the market cap, as cash exceeds debt.

    Market Cap$703.25M
    Enterprise Value$660.44M
    Latest price (Nov 17, 2026)$7.45

    Key Dates

    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 15.81% in the quarter ended Sep 30, 2026 and grew 13.50% a year over 2 years.

    Shares Outstanding85.51M
    Shares Change (YoY)+26.14%
    Shares Change (QoQ)+15.81%
    Share Count Growth (2Y CAGR)+13.50%

    Valuation Ratios

    Sales and book value multiples are 7.0x and 9.3x. Its year-end P/S ranged from 2.7x to 20.0x from 2021 to 2025.

    P/S Ratio7.0x
    Forward P/S7.4x
    P/B Ratio9.3x
    P/TBV Ratio19.6x

    Valuation history and multiples

    Price Statistics

    The stock is up 72.85% over 52 weeks and trades 2.23% below its 50-day average.

    Beta (1Y)1.52
    52-Week Change+72.85%
    1-Month Change+14.79%
    3-Month Change-10.02%
    6-Month Change+59.19%
    5-Year Change-46.23%
    Total Return (1Y)+72.85%
    Total Return (3Y CAGR)+26.50%
    Total Return (5Y CAGR)-13.72%
    Return vs SPY (1Y)+70.59%
    Max Drawdown (1Y)-27.24%
    Max Drawdown (3Y)-52.67%
    Sharpe Ratio (1Y)0.98
    Correlation with SPY (1Y)0.34
    50-Day Average$7.62
    200-Day Average$6.07
    52-Week Range$3.83 to $8.98
    RSI (14 Days)49.6
    Average Volume (20 Days)660.89K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.29x current liabilities, and total debt is 0.74x shareholder equity.

    Current Ratio2.29x
    Quick Ratio2.16x
    Debt / Equity0.74x
    Interest Coverage-11.30x

    Returns and Efficiency

    Return on invested capital is -62.30% over the last 12 months, against a 5-year average of -49.67%.

    Return on Equity (ROE)-118.56%
    Return on Assets (ROA)-43.92%
    Return on Invested Capital (ROIC)-62.30%
    Return on Capital Employed (ROCE)-57.24%
    ROE (5Y Average)-70.99%
    ROA (5Y Average)-37.15%
    ROIC (5Y Average)-49.67%
    Asset Turnover0.52x
    Inventory Turnover4.29x
    Receivables Turnover5.90x
    Cash Conversion Cycle14 days

    Scores

    SOPH has an Altman Z-Score of -1.49, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.49
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $90.97M over the last 12 months is up 24.11% from the 12 months before.

    Revenue$90.97M
    Revenue Growth (YoY)+24.11%
    Gross Profit$60.44M
    Operating Income-$73.21M
    Pretax Income-$80.88M
    Net Income-$81.13M
    EBITDA-$66.20M
    EBIT-$74.30M
    Reported EPS (TTM)-$0.86

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 37.04% of the $184.73M in total assets.

    Cash and Equivalents$93.65M
    Total Debt$50.83M
    Net Cash$42.82M
    Net Cash Per Share$0.50
    Working Capital$70.71M
    Shareholder Equity$68.43M
    Book Value Per Share$0.80
    Tangible Book Value$32.58M
    Tangible Book Per Share$0.38
    Total Assets$184.73M
    Total Liabilities$116.30M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.24M of capital spending, operating cash flow left -$48.52M of free cash flow.

    Operating Cash Flow-$42.28M
    Capital Expenditures$6.24M
    Free Cash Flow-$48.52M
    FCF Per Share-$0.57
    Depreciation and Amortization$10.92M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -80.47%.

    Gross Margin66.43%
    Operating Margin-80.47%
    Pretax Margin-88.91%
    Net Margin-89.18%
    EBITDA Margin-72.78%
    EBIT Margin-81.67%
    FCF Margin-53.34%
    Gross Margin (5Y Average)65.23%

    Growth

    Revenue grew 17.56% a year over 3 years.

    Revenue Growth (3Y CAGR)+17.56%
    Revenue Growth (5Y CAGR)+22.16%
    Book Value Per Share Growth (2Y CAGR)-45.53%
    Tangible Book Per Share Growth (2Y CAGR)-70.62%

    Revenue and profit by year

    Dividends and Yields

    SOPH does not pay a dividend. Its free cash flow yield is -7.62%.

    FCF Yield-7.62%
    Shareholder Yield0.00%

    Peer Position

    Against 11 similar companies, SOPH has the highest P/S.

    P/S Ratio7.0x vs 2.5x median
    ROIC-62.30% vs 2.72% median
    Revenue Growth (Trailing 4 Quarters, YoY)+24.11% vs +7.73% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 23.99% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+23.99%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SOPH

    What is SOPH's market cap?

    Sophia Genetics SA has a market cap of $703.25M. Its enterprise value, which adds debt and subtracts cash, is $660.44M.

    How many shares of SOPH are outstanding?

    Sophia Genetics SA has 85.51M shares outstanding. The count is up 26.14% from a year earlier.

    Does SOPH pay a dividend?

    No. Sophia Genetics SA does not pay a dividend.

    How much debt does SOPH have?

    Sophia Genetics SA has $50.83M of total debt and $93.65M of cash and equivalents, a net cash position of $42.82M.